Inovio Pharmaceuticals Statistics
Share Statistics
Inovio Pharmaceuticals has 36.67M
shares outstanding. The number of shares has increased by 41.51%
in one year.
| Shares Outstanding | 36.67M |
| Shares Change (YoY) | 41.51% |
| Shares Change (QoQ) | 1.57% |
| Owned by Institutions (%) | 47.43% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 15,720 |
| FTD / Avg. Volume | 2.39% |
Short Selling Information
The latest short interest is 6.46M, so 17.63% of the outstanding
shares have been sold short.
| Short Interest | 6.46M |
| Short % of Shares Out | 17.63% |
| Short % of Float | 17.72% |
| Short Ratio (days to cover) | 15.9 |
Valuation Ratios
The PE ratio is -0.46 and the forward
PE ratio is -0.87.
Inovio Pharmaceuticals's PEG ratio is
0.01.
| PE Ratio | -0.46 |
| Forward PE | -0.87 |
| PS Ratio | 228.26 |
| Forward PS | 0.2 |
| PB Ratio | 0 |
| P/FCF Ratio | -0.48 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Inovio Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.77,
with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.77 |
| Quick Ratio | 2.77 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | -114.15 |
| Debt / FCF | -113.47 |
| Interest Coverage | -632.05 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,625.04 |
| Profits Per Employee | $-800,403.93 |
| Employee Count | 134 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -107.15B |
| Effective Tax Rate | 99.9% |
Stock Price Statistics
The stock price has increased by -85.54% in the
last 52 weeks. The beta is 1.41, so Inovio Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.41 |
| 52-Week Price Change | -85.54% |
| 50-Day Moving Average | 1.82 |
| 200-Day Moving Average | 3.97 |
| Relative Strength Index (RSI) | 53.22 |
| Average Volume (20 Days) | 656,486 |
Income Statement
In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K
and earned -107.25M
in profits. Earnings per share was -3.95.
| Revenue | 217.76K |
| Gross Profit | -2.91M |
| Operating Income | -112.4M |
| Net Income | -107.25M |
| EBITDA | -103.95M |
| EBIT | -107.08M |
| Earnings Per Share (EPS) | -3.95 |
Full Income StatementBalance Sheet
The company has 65.81B in cash and 11.87B in
debt, giving a net cash position of 53.95B.
| Cash & Cash Equivalents | 65.81B |
| Total Debt | 11.87B |
| Net Cash | 53.95B |
| Retained Earnings | -1,730.2B |
| Total Assets | 113.2M |
| Working Capital | 62.5M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -104.08M
and capital expenditures 0, giving a free cash flow of -104.56M.
| Operating Cash Flow | -104.08M |
| Capital Expenditures | n/a |
| Free Cash Flow | -104.56M |
| FCF Per Share | -3.85 |
Full Cash Flow StatementMargins
Gross margin is -1337.41%, with operating and profit margins of -51616.91% and -49254.27%.
| Gross Margin | -1337.41% |
| Operating Margin | -51616.91% |
| Pretax Margin | -49254269% |
| Profit Margin | -49254.27% |
| EBITDA Margin | -47735.19% |
| EBIT Margin | -51616.91% |
| FCF Margin | -48019.06% |
